


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I) and pharmaceutically acceptable salts or solvates thereof:



2. (Cancelled)
3. (Currently amended) A method of treating asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis comprising administering a compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 ~~for use as a medicament for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.~~

4. (Currently amended) A method of treating cancer comprising administering a compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 ~~for use as a medicament for the treatment of cancer.~~


5. (Cancelled)

6. (Currently amended) A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering ~~to a patient a therapeutically effective amount of~~ a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

7. (Currently amended) A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering ~~to the patient a therapeutically effective amount of~~ a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

8. (Currently amended) A method of treating a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, in a patient suffering from, or at risk of, said disease, which comprises administering ~~to the patient a therapeutically effective amount of~~ a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

9. (Original) A process for the preparation of a compound of formula (I) which comprises reaction of a compound of formula (II):



(II)

where R is C₁₋₆ alkyl with an acid,
and optionally thereafter forming a pharmaceutically acceptable salt.

10. (Cancelled)

11. (Currently amended) A method combination therapy as claimed in claim 10 for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis, comprising administering a compound of claim 1, formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of claim 1, formula (1), concurrently or sequentially with another therapy and/or another pharmaceutical agent.

12. (Currently amended) A method combination therapy as claimed in claim 10 for the treatment of cancer, comprising administering a compound of claim 1, formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of claim 1, formula (1), concurrently or sequentially with another therapy and/or another pharmaceutical agent.

13. (Currently amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 ~~in association with~~ and a pharmaceutically acceptable adjuvant, diluent or carrier.

14. (Currently amended) A ~~method of treating pharmaceutical composition as claimed in claim 13 for the treatment of~~ asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis comprising administering a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.

15. (Currently amended) A ~~method of treating pharmaceutical composition as claimed in claim 13 for the treatment of~~ cancer comprising administering a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.

16. (Currently amended) A process for the preparation of a pharmaceutical composition as ~~claimed in claim 13~~ comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 ~~in association with~~ and a pharmaceutically acceptable adjuvant, diluent or carrier, which comprises the method comprising mixing a ~~the~~ compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 with a ~~the~~ pharmaceutically acceptable adjuvant, diluent or carrier.

17. (New) A composition comprising a compound of claim 1, formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of claim 1, formula (1), and an agent for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

Applicant : Bonnert
Serial No. : To Be Assigned
Filed : Herewith
Page : 7 of 8

Attorney's Docket No.: 06275-450US1 / 100839-1P US

18. (New) A composition comprising a compound of claim 1, formula (1) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of claim 1, formula (1), and an agent for the treatment of cancer.